Linagliptin Unmasks Specific Antioxidant Pathways Protective Against Albuminuria and Kidney Hypertrophy in a Mouse Model of Diabetes

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Jul 7

PMID 29979777

Citations 13

Authors

Netanya Y Spencer

Zhihong Yang

Jensyn Cone Sullivan

Thomas Klein

Robert C Stanton

Affiliations

Soon will be listed here.

Abstract

Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects on diabetic kidney disease (DKD) via specific antioxidant pathways. The DPP-4 inhibitor, linagliptin, was evaluated with the hypothesis that DPP-4 inhibition would ameliorate the development of DKD in a glucose-independent manner by altering specific antioxidant function.

Methods: DBA/2J mice (a well-characterized model of DKD) and glucose 6-phosphate dehydrogenase (G6PD) deficient mice (a model of impaired antioxidant function) were evaluated. Diabetes was induced by streptozotocin. Mice were divided into: diabetic (DM), diabetic+linagliptin (DM+Lina), and non-diabetic control and treated for 12 weeks.

Results: In DBA/2J mice, there was no difference in body weight and blood glucose between DM and DM+Lina groups. Linagliptin ameliorated albuminuria and kidney hypertrophy in DM DBA/2J mice and specifically increased the mRNA and protein levels for the antioxidants catalase and MnSOD. In G6PD deficient mice, however, increases in these mRNA levels did not occur and linagliptin renoprotection was not observed. Linagliptin also ameliorated histological trends toward mesangial expansion in wild-type mice but not in G6PD deficient mice.

Conclusions: Linagliptin renoprotection involved glucose-independent but antioxidant-enzyme-system-dependent increases in transcription (not just increased protein levels) of antioxidant proteins in wild-type mice. These studies demonstrate that an intact antioxidant system, in particular including transcription of catalase and MnSOD, is required for the renoprotective effects of linagliptin.

Citing Articles

Evaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats.

Morones J, Perez M, Munoz M, Sanchez E, Avila M, Topete J Int J Mol Sci. 2024; 25(21).

PMID: 39518925 PMC: 11545748. DOI: 10.3390/ijms252111372.

Linagliptin ameliorates tacrolimus-induced renal injury: role of Nrf2/HO-1 and HIF-1α/CTGF/PAI-1.

Nady M, El-Raouf O, M El-Sayed E Mol Biol Rep. 2024; 51(1):608.

PMID: 38704766 PMC: 11070395. DOI: 10.1007/s11033-024-09533-2.

Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer.

Zuo B, Li T, Liu X, Wang S, Cheng J, Liu X Clin Transl Oncol. 2023; 25(11):3188-3202.

PMID: 37115489 PMC: 10514125. DOI: 10.1007/s12094-023-03187-5.

Sesquiterpene lactones of : Pharmacology, pharmacokinetics, toxicity, and structure-activity relationship.

Liu X, Li H, Wang S, Zhang J, Liu D Chin Herb Med. 2022; 13(2):167-176.

PMID: 36117502 PMC: 9476744. DOI: 10.1016/j.chmed.2020.11.005.

Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones.

Paco A, Bras T, Santos J, Sampaio P, Gomes A, Duarte M Molecules. 2022; 27(3).

PMID: 35164406 PMC: 8839508. DOI: 10.3390/molecules27031142.

References

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

Hasan A, Hocher B . Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. J Mol Endocrinol. 2017; 59(1):R1-R10. DOI: 10.1530/JME-17-0005. View

Cooper M, Perkovic V, McGill J, Groop P, Wanner C, Rosenstock J . Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. Am J Kidney Dis. 2015; 66(3):441-9. DOI: 10.1053/j.ajkd.2015.03.024. View

Spencer N, Engelhardt J . The basic biology of redoxosomes in cytokine-mediated signal transduction and implications for disease-specific therapies. Biochemistry. 2014; 53(10):1551-64. PMC: 3985689. DOI: 10.1021/bi401719r. View

Nakashima S, Matsui T, Takeuchi M, Yamagishi S . Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res. 2014; 46(10):717-21. DOI: 10.1055/s-0034-1371892. View

Abdelsalam R, Safar M . Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways. J Neurochem. 2015; 133(5):700-7. DOI: 10.1111/jnc.13087. View

Civantos E, Bosch E, Ramirez E, Zhenyukh O, Egido J, Lorenzo O . Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway. Diabetes Metab Syndr Obes. 2017; 10:207-222. PMC: 5473486. DOI: 10.2147/DMSO.S132537. View

Hattori S . Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011; 58(1):69-73. DOI: 10.1507/endocrj.k10e-382. View

Uchii M, Kimoto N, Sakai M, Kitayama T, Kunori S . Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2016; 783:56-63. DOI: 10.1016/j.ejphar.2016.04.005. View

10.

Alkhalaf A, Kleefstra N, Groenier K, Bilo H, Gans R, Heeringa P . Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One. 2012; 7(7):e40427. PMC: 3391239. DOI: 10.1371/journal.pone.0040427. View

11.

Kitada M, Ogura Y, Koya D . Rodent models of diabetic nephropathy: their utility and limitations. Int J Nephrol Renovasc Dis. 2016; 9:279-290. PMC: 5115690. DOI: 10.2147/IJNRD.S103784. View

12.

Heise T, Graefe-Mody E, Huttner S, Ring A, Trommeshauser D, Dugi K . Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009; 11(8):786-94. DOI: 10.1111/j.1463-1326.2009.01046.x. View

13.

Fujita H, Fujishima H, Chida S, Takahashi K, Qi Z, Kanetsuna Y . Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol. 2009; 20(6):1303-13. PMC: 2689908. DOI: 10.1681/ASN.2008080844. View

14.

Qi Z, Fujita H, Jin J, Davis L, Wang Y, Fogo A . Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes. 2005; 54(9):2628-37. DOI: 10.2337/diabetes.54.9.2628. View

15.

Jain M, Cui L, Brenner D, Wang B, Handy D, Leopold J . Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase. Circulation. 2004; 109(7):898-903. DOI: 10.1161/01.CIR.0000112605.43318.CA. View

16.

Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland R . A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care. 2010; 33(7):1598-601. PMC: 2890365. DOI: 10.2337/dc09-2241. View

17.

Meister A . Glutathione metabolism and its selective modification. J Biol Chem. 1988; 263(33):17205-8. View

18.

Avila D, de Araujo G, Silva M, de Amorim Miranda P, Diniz M, Pedrosa M . Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Arch Med Res. 2013; 44(3):194-202. DOI: 10.1016/j.arcmed.2013.03.004. View

19.

Pujadas G, De Nigris V, Prattichizzo F, La Sala L, Testa R, Ceriello A . The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine. 2016; 56(3):509-520. PMC: 5435779. DOI: 10.1007/s12020-016-1052-0. View

20.

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View